Norma M. B. Benevides

Norma M. B. Benevides


Research Focus & Metrics

Academic Career Length

45Years (1982-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2010 in Carbohydrate Polymers
Verified
Journal Article
Closed access
FSF.R.F. Silva
F.R.F. Silva
CDC.M.P.G. Dore
C.M.P.G. Dore
CMC.T. Marques
C.T. Marques
MNM.S. Nascimento
M.S. Nascimento
NBNorma M. B. Benevides
Norma M. B. Benevides
ELE.L. Leite
E.L. Leite

1 May 2015 in Food Hydrocolloids
Verified
Journal Article
Closed access
GPGabriela A. Paula
Gabriela A. Paula
NBNorma M. B. Benevides
Norma M. B. Benevides
ACArcelina P. Cunha
Arcelina P. Cunha
AOAna Vitória de Oliveira
Ana Vitória de Oliveira
APAlaídes M.B. Pinto
Alaídes M.B. Pinto
HAHenriette Azeredo
Henriette Azeredo

1 June 2018 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
RBRicardo Basto
Ricardo Basto
AFAnnyta Fernandes Frota
Annyta Fernandes Frota
Joana SilvaJoana Silva
Joana Silva
Celso AlvesCelso Alves
Celso Alves
ANAgnieszka Zofia Neugebauer
Agnieszka Zofia Neugebauer
NBNorma M. B. Benevides
Norma M. B. Benevides

1 September 2005 in Carbohydrate Research
Verified
Journal Article
Closed access
MPMaria G. Pereira
Maria G. Pereira
NBNorma M. B. Benevides
Norma M. B. Benevides
MMMarcia R.S. Melo
Marcia R.S. Melo
AVAna Paula Valente
Ana Paula Valente
FMFábio R. Melo
Fábio R. Melo
PMPaulo A.S. Mourão
Paulo A.S. Mourão

25 March 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CCChistiane Oliveira Coura
Chistiane Oliveira Coura
RBRicardo Basto
Ricardo Basto
JRJosé Ariévilo Gurgel Rodrigues
José Ariévilo Gurgel Rodrigues
EVEdfranck de Sousa Oliveira Vanderlei
Edfranck de Sousa Oliveira Vanderlei
IAIanna Wivianne Fernandes de Araújo
Ianna Wivianne Fernandes de Araújo
NBNorma M. B. Benevides
Norma M. B. Benevides
The anti-inflammatory mechanisms of the sulfated polysaccharidic fraction obtained from red marine alga Gracilaria cornea (Gc-FI) were investigated using a paw edema model induced in rats by different inflammatory agents (carrageenan, dextran, serotonin, bradykinin, compound 48/80 or L-arginine). Gc-FI at the doses of 3, 9 or 27 mg/kg, subcutaneously - s.c., significantly inhibited rat paw edema induced by carrageenan and dextran, as confirmed by myeloperoxidase and Evans’ blue assessments, respectively. Gc-FI (9 mg/kg, s.c.) inhibited rat paw edema induced by histamine, compound 48/80 and L-arginine. Additionally, Gc-FI (9 mg/kg, s.c.) inhibited Cg-induced edema in animals with intact mast cells but did not inhibit that with degranulated mast cells by compound 48/80, revealing a protective role on mast cell membranes. Gc-FI down-regulated the IL-1β, TNF-α and COX-2 mRNA and protein levels compared with those of the carrageenan group, based on qRT-PCR and immunohistochemistry analyses. After inhibition with ZnPP IX, a specific heme oxygenase-1 (HO-1) inhibitor, the anti-inflammatory effect of Gc-FI was not observed in Cg-induced paw edema, suggesting that the anti-inflammatory effect of Gc-FI is, in part, dependent on the integrity of the HO-1 pathway. Gc-FI can target a combination of multiple points involved in inflammatory phenomena.

1 January 2008 in Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
RFRoberto Fonseca
Roberto Fonseca
SOStephan-Nicollas M. C. G. Oliveira
Stephan-Nicollas M. C. G. Oliveira
FMFábio R. Melo
Fábio R. Melo
MPMaria G. Pereira
Maria G. Pereira
NBNorma M. B. Benevides
Norma M. B. Benevides
PMPaulo Mourao
Paulo Mourao
We compared sulfated galactans (SGs) from two species of red algae using specific coagulation assays and experimental models of thrombosis.These polysaccharides have an identical saccharide structure and the same size chain, but with slight differences in their sulfation patterns.As a consequence of these differences, the two SGs differ in their anticoagulant and venous antithrombotic activities.SG from G.crinale exhibits procoagulant and prothrombotic effects in low doses (up to 1.0 mg/kg body weight), but in high doses (>1.0 mg/kg) this polysaccharide inhibits both venous and arterial thrombosis in rats and prolongs ex-vivo recalcification time. In contrast, SG from B. occidentalis is a very potent anticoagulant and antithrombotic compound in low doses (up to 0.5 mg/kg body weight), inhibiting venous experimental thrombosis and prolonging ex-vivo recalcification time, but these effects are reverted in high doses. Only at high doses (>1.0 mg/kg) the SG from B. occidentalis inhibits arterial thrombosis. As with heparin, SG from G. crinale does not activate factor XII, while the polysaccharide from B. occidentalis activates factor XII in high concentrations, which could account for its procoagulant effect at high doses on rats. Both SGs do not modify bleeding time in rats.These results indicate that slight differences in the proportions and/or distribution of sulfated residues along the galactan chain may be critical for the interaction between proteases, inhibitors and activators of the coagulation system, resulting in a distinct pattern in anti- and procoagulant activities and in the antithrombotic action.